Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 1.01.

  • ImmunityBio's Equity Ratio rose 5050.6% to 1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.01, marking a year-over-year increase of 5050.6%. This contributed to the annual value of 1.28 for FY2024, which is 976.51% down from last year.
  • Per ImmunityBio's latest filing, its Equity Ratio stood at 1.01 for Q3 2025, which was up 5050.6% from 1.42 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Equity Ratio registered a high of 0.52 during Q4 2021, and its lowest value of 2.22 during Q2 2023.
  • Its 5-year average for Equity Ratio is 1.29, with a median of 1.24 in 2022.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 97838.83% in 2021, then soared by 5050.6% in 2025.
  • Over the past 5 years, ImmunityBio's Equity Ratio (Quarter) stood at 0.52 in 2021, then tumbled by 138.65% to 1.24 in 2022, then grew by 6.26% to 1.16 in 2023, then decreased by 9.77% to 1.28 in 2024, then rose by 20.9% to 1.01 in 2025.
  • Its Equity Ratio was 1.01 in Q3 2025, compared to 1.42 in Q2 2025 and 1.95 in Q1 2025.